Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides

Luo, Xiaofang; Chen, Huifang; Song, Yannan; Qin, Zuodong; Xu, Lijian; He, Nongyue; Tan, Yimin; Dessie, Wubliker

doi:10.1016/j.ejps.2022.106363

Cited by 45 publications

(27 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the ERT and SRT treatment for GD, ND7 showed unique functions, including BBB penetration, ameliorated GD and nGD phenotypes, and prevention of the neurodegenerative markers (30). In addition, the development of peptidebased drug has more advantages, including high potency, low cost and potential low toxicity, et al (44,45). Our study showed that ERp57 plays an important role in the regulation of both PGRN and its derivative ND7, in type 2 neuropathic GD patient fibroblasts.…”

Section: Wwwbiosciencetrendscommentioning

confidence: 70%

Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease

Liu

Zhao

Jian

et al. 2023

BST

View full text Add to dashboard Cite

Gaucher disease (GD), one of the most common lysosomal storage diseases, is caused by GBA1 mutations resulting in defective glucocerebrosidase (GCase) and consequent accumulation of its substrates β-glucosylceramide (β-GlcCer). We reported progranulin (PGRN), a secretary growth factorlike molecule and an intracellular lysosomal protein was a crucial co-factor of GCase. PGRN binds to GCase and recruits Heat Shock Protein 70 (Hsp70) to GCase through its C-terminal Granulin (Grn) E domain, termed as ND7. In addition, both PGRN and ND7 are therapeutic against GD. Herein we found that both PGRN and its derived ND7 still displayed significant protective effects against GD in Hsp70 deficient cells. To delineate the molecular mechanisms underlying PGRN's Hsp70-independent regulation of GD, we performed a biochemical co-purification and mass spectrometry with His-tagged PGRN and His-tagged ND7 in Hsp70 deficient cells, which led to the identification of ERp57, also referred to as protein disulfide isomerase A3 (PDIA3), as a protein that binds to both PGRN and ND7. Within type 2 neuropathic GD patient fibroblasts L444P, bearing GBA1 L444P mutation, deletion of ERp57 largely abolished the therapeutic effects of PGRN and ND7, as manifested by loss of effects on lysosomal storage, GCase activity, and β-GlcCer accumulation. Additionally, recombinant ERp57 effectively restored the therapeutic effects of PGRN and ND7 in ERp57 knockout L444P fibroblasts. Collectively, this study reports ERp57 as a previously unrecognized binding partner of PGRN that contributes to PGRN regulation of GD.

show abstract

Section: Wwwbiosciencetrendscommentioning

confidence: 70%

Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease

Liu

Zhao

Jian

et al. 2023

BST

View full text Add to dashboard Cite

show abstract

“…(2) Good tumor/normal tissue concentration ratio 24,57,59-61 ; (3) Low cytotoxicity 24,57,[59][60][61]101 ;…”

Section: Aminoacids/ Peptidementioning

confidence: 99%

Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment

Coghi

Hosmane

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is one of the most promising treatments among neutron capture therapies due to its long‐term clinical application and unequivocally obtained success during clinical trials. Boron drug and neutron play an equivalent crucial role in BNCT. Nevertheless, current clinically used l‐boronophenylalanine (BPA) and sodium borocaptate (BSH) suffer from large uptake dose and low blood to tumor selectivity, and that initiated overwhelm screening of next generation of BNCT agents. Various boron agents, such as small molecules and macro/nano‐vehicles, have been explored with better success. In this featured article, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective view for the future of BNCT in cancer treatment. This review aims at summarizing the current knowledge of a variety of boron compounds, reported recently, for the application of BCNT.

show abstract

“…However, nanodelivery systems using AMPs are at an early stage of development and are still in the laboratory phase of development. There are also some challenges to incorporate AMPs into nanodelivery systems . Improving the activity and biocompatibility of AMPs is another strategy being explored.…”

Section: Delivery Challenges Of Ampsmentioning

confidence: 99%

Advances in Transdermal Delivery of Antimicrobial Peptides for Wound Management: Biomaterial-Based Approaches and Future Perspectives

Firdous,

Sagor,

Arafat

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs), distinguished by their cationic and amphiphilic nature, represent a critical frontier in the battle against antimicrobial resistance due to their potent antimicrobial activity and a broad spectrum of action. However, the clinical translation of AMPs faces hurdles, including their susceptibility to degradation, limited bioavailability, and the need for targeted delivery. Transdermal delivery has immense potential for optimizing AMP administration for wound management. Leveraging the skin's accessibility and barrier properties, transdermal delivery offers a noninvasive approach that can circumvent systemic side effects and ensure sustained release. Biomaterialbased delivery systems, encompassing nanofibers, hydrogels, nanoparticles, and liposomes, have emerged as key players in enhancing the efficacy of transdermal AMP delivery. These biomaterial carriers not only shield AMPs from enzymatic degradation but also provide controlled release mechanisms, thereby elevating stability and bioavailability. The synergistic interaction between the transdermal approach and biomaterial-facilitated formulations presents a promising strategy to overcome the multifaceted challenges associated with AMP delivery. Integrating advanced technologies and personalized medicine, this convergence allows the reimagining of wound care. This review amalgamates insights to propose a pathway where AMPs, transdermal delivery, and biomaterial innovation harmonize for effective wound management.

show abstract

Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides

Cited by 45 publications

References 161 publications

Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease

Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease

Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment

Advances in Transdermal Delivery of Antimicrobial Peptides for Wound Management: Biomaterial-Based Approaches and Future Perspectives

Contact Info

Product

Resources

About